Artera comes out of stealth with the funding announcement.

Artera, a developer of AI-based predictive and prognostic cancer tests, has launched publicly with $90 million in funding from a group of tech and healthcare investors. The investment will support the distribution of Artera’s flagship test, the ArteraAI Prostate Test, which is the first test to predict therapy benefit in localized prostate cancer.

The funding will also advance the development of tests across different cancers. Investors included seven institutions namely Coatue, Johnson & Johnson Innovation – JJDC, Inc., Koch Disruptive Technologies, Walden Catalyst Ventures, TIME Ventures, Breyer Capital, and The Factory. Angel investors Marc Benioff, Jim Breyer, Lip-Bu Tan, Chris Re, Andy Jacques, Amarjit Gill, Jeff Dean, Steve Blank, Dennis Wong, Clarence So, and Michael Driscoll also participated. (Businesswire)

“In the last 18 months, Artera’s AI-informed approach to personalized cancer treatment has unlocked commercial and regulatory traction well ahead of genomic competitors,” said Stephen Cho, Partner at Coatue.

Investor Marc Benioff said Artera was “one of the greatest advances in prostate oncology in the last 20 years.”

Artera aims to provide risk stratification and prediction of therapeutic benefit to enable personalized, shared decision-making for patients and clinicians.

Related Story:  The FDA Clears ProstatID, An AI That Helps Detect Prostate Cancer From MRIs

Image Credit: Flickr